VOMETA FT Tablet

Indication:

・Acute nausea and vomiting. It is not recommended for the routine prophylaxis of postoperative vomiting.

・Nausea and vomiting caused by levodopa and bromocriptine. It is recommended that treatment with domperidone should not exceed a period of 12 weeks.

・Treatment for functional dyspepsia symptoms. It is not recommended for the long-term administration.

・Acute nausea and vomiting caused by cancer chemotherapy and radiotherapy.

Dosage and administrations:

・Functional dyspepsia

Adults and elderly: 10-20mg, 3 times daily before meals and 10-20mg before bedtime, depending on clinical response.

The treatment should not exceed 12 weeks.

・Nausea and vomiting (including caused by levodopa and bromocriptine)

Adults and elderly: 10-20mg, with 4-8 hours interval.

Children, associated with cancer chemotherapy and radiotherapy: 0.2-0.4mg/kg body weight/day with 4-8 hours interval.

Drug should be taken 15-30 minutes before meals and before bedtime.

VOMETA FT in the form of fast-melting tablets, can be swallowed without water.

・Patients with known hypersensitivity to domperidone.

・Patients with a prolactinoma (protein-releasing pituitary tumor).

Functional dyspepsia

Adults and elderly: 10-20mg, 3 times daily vefore meals and 10-20mg before bedtime, dependeing on clinical response.

The treatment should not exceed 12 weeks.

Nausea and vomiting (including caused by levodopa and bromocriptine)

Adults and elderly: 10-20mg, with 4-8 hours interval.

Children, associated with cancer chemotherapy and radiotherapy: 0.2-0.4mg/kg body weight/day with 4-8 hours interval.

Drug should be taken 15-30 minutes before meals and before bedtime.

It can be swallowed without water.

・Rarely: sedation, extrapyramidal dystonic reactions, parkinsonism and tardive dyskinesia, inadult and elderly and may be treated with antiparkinsonian drugs.

・Produces a rise in serum prolactin concentration, and this may be lead to galactorrhea and gynecomastia.

・Dry mouth, headache, diarrhea, skin rash, thirst, nervousness, and itch.

・Domperidone may reduce the hypoprolactinemic effect of bromocriptine.

・Concomitant administration of muscarinic anticholinergic and opioid analgesic drugs may antagonize the effect of domperidone.

・Concomitant administration of antacids may lower the bioavailability of domperidone.

・BIoavailability is increased from 13% to 23% if given 1.5 hours after a meal.

no lists

- should be used with caution in pregnant and nursing women.

- It is not recommended to give VOMETA FT for long-term treatment.

- Should be used with caution in patients with hepatic and renal dysfunction.

Domperidone is a dopamine antagonist with antiemetic properties. Its natiemetic effect may be due to a combination of peripheral (gastrokinetic) effects and antagonism of dopamine receptors in the chemoreceptor tigger zone, which lies outside the blood-brain barrier in the area postrema. Oral administration of domperidone increases the duration of antral and duodenal contractions, increases the gastric emptying of liquids and semi-solids in healthy subjects, and or solids in patients in whom it was delayed, and increases lower esophageal sphincter pressure in healthy subjects.